Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Neuro-Oncology|July 7, 2021
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubulesDanielle M Burgenske, Surabhi Talele, Jenny L Pokorny, et al.
Communications Biology|June 20, 2023
Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomasCecile Riviere-Cazaux, Lucas P Carlstrom, Karishma Rajani, et al.
Neuro-Oncology Advances|September 8, 2022
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenograftsKendra A Porath, Michael S Regan, Jessica I Griffith, et al.
Molecular Cancer Therapeutics|October 23, 2024
DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway DeficitsSonja Dragojevic, Emily J Smith, Michael S Regan, et al.
Neuro-Oncology|September 8, 2025
Window of opportunity evaluation of blood-brain barrier permeability heterogeneity within and across high-grade glioma patientsJu-Hee Oh, Sarah K Reed, Cecile Riviere-Cazaux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type GlioblastomaRachael A Vaubel, Wenjuan Zhang, Ju-Hee Oh, et al.
Nature Communications|November 23, 2018
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastomaElizabeth C Randall, Kristina B Emdal, Janice K Laramy, et al.
Neuro-Oncology|May 29, 2021
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastomaBianca-Maria Marin, Kendra A Porath, Sonia Jain, et al.
Pageof 12